慢性片頭痛の予防治療におけるTEV-48125の皮下投与2用量レジメンとプラセボの有効性および安全性の比較
基本情報
- NCT ID
- NCT02621931
- ステータス
- 完了
- 試験のフェーズ
- 第3相
- 試験タイプ
- 介入
- 目標被験者数
- 1,130
- 治験依頼者名
- Teva Branded Pharmaceutical Products R&D, Inc.
概要
The study is being conducted to evaluate two doses of TEV-48125 in adult patients with chronic migraine
対象疾患
介入
依頼者（Sponsor）
実施施設 (24)
Teva Investigational Site 84064
Tokyo, Japan
Teva Investigational Site 84069
Kai, Japan
Teva Investigational Site 84071
Toyonaka-shi, Japan
Teva Investigational Site 84070
Saitama-shi, Japan
Teva Investigational Site 84064
Chofu-shi, Japan
Teva Investigational Site 84062
Osaka, Japan
Teva Investigational Site 84069
Kaisho, Japan
Teva Investigational Site 84066
Kagoshima, Japan
Teva Investigational Site 84067
Kyoto, Japan
Teva Investigational Site 84066
Kagoshima, Japan
Teva Investigational Site 84071
Toyonaka, Japan
Teva Investigational Site 84065
Tochigi, Japan
Teva Investigational Site 84067
Kyoto, Japan
Teva Investigational Site 84073
Kawasaki, Japan
Teva Investigational Site 84072
Chofu-shi, Japan
Teva Investigational Site 84072
Chofu-shi, Japan
Teva Investigational Site 84068
Shizuoka, Japan
Teva Investigational Site 84073
Kawasaki-shi, Japan
Teva Investigational Site 84061
Sendai, Japan
Teva Investigational Site 84062
Osaka, Japan
Teva Investigational Site 84065
Shimotsuma, Japan
Teva Investigational Site 84070
Saitama, Japan
Teva Investigational Site 84068
Shizuoka, Japan
Teva Investigational Site 84061
Sendai, Japan